

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this paper (along with any paper referred to as being transmitted therewith) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, Washington, D.C. 20231.

John P. Parise  
(Print Name)

Date: June 1, 2000

(Signature)

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Patent Application

FEB 21 2006

Binggeli et al.

Group: 1613 OFFICE OF PATENTS

Serial No. 08/711,339, filed September 6, 1996

Examiner: R. Ramseur

For: **NOVEL PIPERIDINE DERIVATIVES HAVING RENIN INHIBITING ACTIVITY**

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Nutley, New Jersey 07110  
June 1, 2000

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.


Documents A5 and A6 listed on Form PTO-1449 are enclosed.

Serial No. 08/711,339  
Filed: September 6, 1996

Consideration of all the documents cited on Form PTO-1449 is requested.

Since the Information Disclosure Statement is submitted after the first Office Action on the merits and after three months of the filing date for the captioned application, there is enclosed a Fee Sheet.

Respectfully submitted,



\_\_\_\_\_  
Attorney for Applicant(s)

John F. Parise  
(Reg. No. 34403)  
340 Kingsland Street  
Nutley, New Jersey 07110  
Telephone: (973) 235-6326  
Telefax: (973) 235-2363

99096

Filing Date  
September 6, 1996

Group  
1613

[illegible][illegible][illegible]

DATE CONSIDERED

\*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.